| 0.6199 0.127 (25.74%) | 03-31 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.02  |
1-year : | 1.3 |
| Resists | First : | 0.87 |
Second : | 1.12 |
| Pivot price | 0.67 |
|||
| Supports | First : | 0.49 | Second : | 0.4 |
| MAs | MA(5) : | 0.54 |
MA(20) : | 0.76 |
| MA(100) : | 1.09 |
MA(250) : | 1.45 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 8.5 |
D(3) : | 4.7 |
| RSI | RSI(14): 32.8 |
|||
| 52-week | High : | 6.19 | Low : | 0.49 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CTOR ] has closed above bottom band by 38.8%. Bollinger Bands are 44% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.65 - 0.66 | 0.66 - 0.66 |
| Low: | 0.48 - 0.49 | 0.49 - 0.49 |
| Close: | 0.61 - 0.62 | 0.62 - 0.63 |
Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.
Tue, 31 Mar 2026
Citius Oncology reports strong early LYMPHIR launch with broad payer coverage and institutional uptake - TradingView
Tue, 31 Mar 2026
Early LYMPHIR launch traction at Citius Oncology (Nasdaq: CTOR) - Stock Titan
Tue, 24 Mar 2026
Citius Oncology (NASDAQ:CTOR) Trading Down 2.8% - Here's What Happened - MarketBeat
Fri, 13 Feb 2026
First LYMPHIR cancer drug sales bring in $3.9M for Citius Oncology - Stock Titan
Wed, 11 Feb 2026
Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar - PR Newswire
Tue, 23 Dec 2025
Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 88 (M) |
| Shares Float | 14 (M) |
| Held by Insiders | 83.8 (%) |
| Held by Institutions | 8.1 (%) |
| Shares Short | 1,040 (K) |
| Shares Short P.Month | 914 (K) |
| EPS | -0.32 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.68 |
| Profit Margin | 0 % |
| Operating Margin | -133.2 % |
| Return on Assets (ttm) | -14 % |
| Return on Equity (ttm) | -47.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.03 |
| Sales Per Share | 0.04 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -13 (M) |
| Levered Free Cash Flow | -25 (M) |
| PE Ratio | -2 |
| PEG Ratio | 0 |
| Price to Book value | 0.89 |
| Price to Sales | 13.88 |
| Price to Cash Flow | -4.26 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|